News coverage about Strongbridge Biopharma PLC (NASDAQ:SBBP) has been trending somewhat positive on Friday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Strongbridge Biopharma PLC earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.6168724267607 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- 13D Filing: Caxton Corp and Strongbridge Biopharma PLC (SBBP) (insidermonkey.com)
- ChemoCentryx (CCXI) & Strongbridge Biopharma PLC (SBBP) Head to Head Analysis (americanbankingnews.com)
- Strongbridge Biopharma PLC (SBBP) versus Chiasma (CHMA) Head-To-Head Analysis (americanbankingnews.com)
- Strongbridge Biopharma plc Announces Closing of Public Offering of Ordinary Shares (finance.yahoo.com)
- Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares (finance.yahoo.com)
A number of equities analysts recently commented on the stock. Oppenheimer Holdings, Inc. assumed coverage on shares of Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price target on the stock. Zacks Investment Research raised shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating and set a $7.25 price target on the stock in a research report on Wednesday. Finally, ValuEngine raised shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $11.81.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.34). The firm had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.84 million. Analysts expect that Strongbridge Biopharma PLC will post ($2.28) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/13/strongbridge-biopharma-plc-sbbp-given-daily-coverage-optimism-rating-of-0-01.html.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
What are top analysts saying about Strongbridge Biopharma PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Strongbridge Biopharma PLC and related companies.